What is the approximate price of Alpelisib in India?

Alpelisib(Alpelisib)-Piqray, developed by Novartis, is the world's first approved PI3Kα selective inhibitor. As an original drug, it is marketed in many countries around the world, including the United States, the European Union, Japan and other places. In India, Novartis has also launched the genuine version of Piqray, which is the original Indian version and not a generic drug. This provides patients in South Asia and surrounding countries with more accessible medication options.

Currently, most Piqray sold in the Indian market is 150mg*28 tablets, and the price per box is about RMB 7,000 (which may fluctuate slightly depending on exchange rate changes). Compared with the pricing in European and American markets, this price is obviously more affordable. The Indian version of Piqray is produced by the Indian subsidiary of Novartis Pharmaceuticals. The drug packaging, batch number and security code are consistent with the international version and comply with the quality standards of the local Food and Drug Administration (CDSCO). Therefore, its efficacy and safety are consistent with the global original version, but its pricing strategy is more in line with local market conditions.

In India,Piqray is mainly supplied through oncology pharmacies and authorized distribution channels. Some international patients obtain Indian versions of original drugs through cross-border drug service agencies to replace high-priced European and American drugs. However, in China, if patients purchase or import drugs by themselves, they need to understand their legality and regulatory requirements. Only by obtaining and providing prescription certificates through formal institutions can you ensure the safety of the source of medication.

Another factor that affects drug prices is specifications and market fluctuations. Some regions also provide 300mg combination packaging, and the price is usually higher than the 150mg single box product. In addition, different agents and exchange rate changes will affect retail prices. If calculated based on long-term medication, the Indian version of Piqray can save patients nearly half of their expenses in terms of cost, so it is regarded as a "cost-effective original drug".

It needs to be emphasized that although the price of Piqray is lower in India it should still be used under the guidance of a doctor. When choosing a channel, patients should first confirm whether the drug source comes from an authorized pharmacy and avoid purchasing unregulated informal versions.

Reference materials:https://www.piqray.com/